QCM
ALDX icon

Quantinno Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Quantinno Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,988
Closed -$238K – 3302
2025
Q4 		$238K Sell
45,988
-5,336
-10% -$27.4K ﹤0.01% 2967
2025
Q3 		$268K Buy
+51,324
New +$268K ﹤0.01% 2551

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quantinno Capital Management's ALDX Position: Q1 2026 in Review

Quantinno Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 45,988 shares — an estimated $238K sold.

Quantinno Capital Management first reported a position in ALDX in Q3 2025 and held it in 2 quarters. The position peaked at $268K in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Quantinno Capital Management reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quantinno Capital Management sold 45,988 Aldeyra Therapeutics shares in Q1 2026, an estimated $238K.
  • Quantinno Capital Management first reported a position in Aldeyra Therapeutics in Q3 2025 and held it in 2 quarters.
  • Quantinno Capital Management's Aldeyra Therapeutics position peaked at $268K in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Quantinno Capital Management's 13F filing for Q1 2026, filed 15 May 2026.